Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

  • End date
    Nov 4, 2023
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 4 February 2021


This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.

Condition Relapsed Refractory Multiple Myeloma
Treatment Ipilimumab
Clinical Study IdentifierNCT04635735
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on4 February 2021


Yes No Not Sure

Inclusion Criteria

Inclusion Criteria prior to Allogeneic Hematopoietic Stem Cell Transplantation
Willing and able to participate as a research subject and provide informed consent (Note: an LAR may sign the consent form on the partipant's behalf)
Diagnosis of relapsed refractory multiple myeloma defined as more than 2 lines of prior therapy with at least a very good partial remission to most recent salvage therapy
Patients should have R-ISS stage II or III disease at diagnosis or high risk cytogenetics by IMWG criteria (t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q)) at any time since diagnosis
Note:. A line of therapy is treatment between diagnosis and progression or
between two progressions
Eligible for CD34-selected HSCT according to MSKCC adult BMT guidelines
Have a 10/10 matched donor
Age 21, < 73 years
Karnofsky (adult) Performance Status 70%
Patients must have adequate organ function measured by
Cardiac: LVEF at rest must be 50%
< 3x ULN ALT
< 1.5 ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia. 3. Renal: serum creatinine <1.2 mg/dl or if serum creatinine is outside the normal range, then CrCl > 40 ml/min (measured or calculated/estimated) with dose adjustment of Fludarabine for <70ml/min 4. Pulmonary: DLCO > 50% of predicted (corrected for hemoglobin)
Inclusion Criteria prior to Ipilimumab
Non progressive myeloma (partial response or better) as defined by International Myeloma Working Group (IMWG) criteria
Engraftment of all cell lines without transfusion dependence, defined as
absolute neutrophil count > 1.0K/mcL x 3 consecutive days
platelets > 50K/mcLx 7 consecutive days without platelet transfusion
no platelet or RBC transfusions within the preceding 7 days
% donor chimerism in the bone marrow

Exclusion Criteria

Exclusion Criteria prior to Allogeneic Hematopoietic Stem Cell Transplantation
Patients ineligible for therapy with ipilimumab, for example
Active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive medications at enrollment. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
History of motor neuropathy considered to be of autoimmune origin (e.g., Guillain-Barre Syndrome, Myasthenia Gravis)
Female patients who are pregnant or breast-feeding
Patients with plasma cell leukemia at the time of diagnosis
Patients who have undergone prior allogeneic hematopoietic stem cell transplantation
Patients who have had a previous malignancy that is not in remission
Exclusion Criteria prior to Ipilimumab
Active infection or treatment for infection (patients on Cytomegalovirus (CMV) therapy will be considered eligible; patients with CMV viremia by PCR or disease with end-organ involvement will not be eligible)
Active GVHD of any grade or prior grade 3-4 GVHD
Active immune suppression, defined as
active use of calcineurin inhibitors, mycophenolate mofetil, or other immunomodulators
steroid dosing exceeding 10 mg/d prednisone or equivalent
Receiving immunomodulatory agents (ex. thalidomide, lenalidomide, pomalidomide)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note